Human papillomavirus infection as a prognostic marker for lung adenocarcinoma: a systematic review and meta-analysis
- PMID: 28427144
- PMCID: PMC5470986
- DOI: 10.18632/oncotarget.15671
Human papillomavirus infection as a prognostic marker for lung adenocarcinoma: a systematic review and meta-analysis
Abstract
Although a number of studies have investigated the association between human papillomavirus (HPV) and lung cancer prognosis, the results remain inconsistent. We therefore conducted a meta-analysis of epidemiologic studies to address this issue. Searches of the MEDLINE and EMBASE electronic databases from their inception until June 30, 2016 yielded nine studies involving a total of 1,205 lung cancer cases that were used to conduct the meta-analysis. Study-specific risk estimates were pooled using a random-effects model. The pooled hazard ratio (HR) comparing HPV-positive to HPV-negative cancers 1.00 (95% confidence interval (CI): 0.78-1.28) was not significantly correlated with overall survival. However, lung adenocarcinoma patients with HPV infections exhibited a survival benefit compared to those without HPV infection (HR=0.69, 95% CI: 0.50-0.96). This meta-analysis suggests HPV infection is a prognostic marker in lung adenocarcinoma. To further elucidate the epidemiology and pathogenesis of HPV infections in lung cancer, future large prospective studies are encouraged to stratify survival analysis based on the pathological type and clinical stage of the cancer.
Keywords: HPV; lung cancer; meta-analysis; prognosis.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures




Similar articles
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
The association between human papillomavirus and bladder cancer: Evidence from meta-analysis and two-sample mendelian randomization.J Med Virol. 2023 Jan;95(1):e28208. doi: 10.1002/jmv.28208. Epub 2022 Oct 25. J Med Virol. 2023. PMID: 36226344 Free PMC article.
Cited by
-
Presence and activity of HPV in primary lung cancer.J Cancer Res Clin Oncol. 2018 Dec;144(12):2367-2376. doi: 10.1007/s00432-018-2748-8. Epub 2018 Sep 17. J Cancer Res Clin Oncol. 2018. PMID: 30225539 Free PMC article.
-
Human papillomavirus infection maybe not associated with primary lung cancer in the Fujian population of China.Thorac Cancer. 2020 Mar;11(3):561-569. doi: 10.1111/1759-7714.13282. Epub 2020 Jan 23. Thorac Cancer. 2020. PMID: 31971663 Free PMC article.
-
Human papilloma virus: global research architecture assessed by density-equalizing mapping.Oncotarget. 2018 Apr 24;9(31):21965-21977. doi: 10.18632/oncotarget.25136. eCollection 2018 Apr 24. Oncotarget. 2018. PMID: 29774116 Free PMC article.
-
Infection with human cytomegalovirus, Epstein-Barr virus, and high-risk types 16 and 18 of human papillomavirus in EGFR-mutated lung adenocarcinoma.Croat Med J. 2023 Apr 30;64(2):84-92. doi: 10.3325/cmj.2023.64.84. Croat Med J. 2023. PMID: 37131310 Free PMC article.
-
Construction of a New Immune-Related Competing Endogenous RNA Network with Prognostic Value in Lung Adenocarcinoma.Mol Biotechnol. 2024 Feb;66(2):300-310. doi: 10.1007/s12033-023-00754-7. Epub 2023 Apr 28. Mol Biotechnol. 2024. PMID: 37118319
References
-
- Ervik M, Lam M, Ferlay J, Mery L, Soerjomataram I, Bray F. Cancer Today. Lyon, France: International Agency for Research on Cancer; 2016. Cancer Today. Available from: http://gco.iarc.fr/ today, accessed [09/07/2016]
-
- Hajdu SI, Ali SZ. Discovery of human papillomavirus in carcinoma of the lung. Annals of clinical and laboratory science. 2008;38:3–5. - PubMed
-
- de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. The Lancet Infectious diseases. 2007;7:453–459. - PubMed
-
- Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsague X, Laporte L, Bosch FX, de Sanjose S, Trottier H. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. The Lancet Oncology. 2014;15:1319–1331. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical